Xiao Yuxuan, Li Yutao, Jing Xilin, Weng Lin, Liu Xu, Liu Qingyun, Chen Kezhong
Department of Thoracic Surgery, Peking University People's Hospital, Beijing 100044, China.
Thoracic Oncology Institute, Peking University People's Hospital, Beijing 100044, China.
Cancer Biol Med. 2025 Jul 24;22(8):903-27. doi: 10.20892/j.issn.2095-3941.2025.0127.
Organoids are three-dimensional stem cell-derived models that offer a more physiologically relevant representation of tumor biology compared to traditional two-dimensional cell cultures or animal models. Organoids preserve the complex tissue architecture and cellular diversity of human cancers, enabling more accurate predictions of tumor growth, metastasis, and drug responses. Integration with microfluidic platforms, such as organ-on-a-chip systems, further enhances the ability to model tumor-environment interactions in real-time. Organoids facilitate in-depth exploration of tumor heterogeneity, molecular mechanisms, and the development of personalized treatment strategies when coupled with multi-omics technologies. Organoids provide a platform for investigating tumor-immune cell interactions, which aid in the design and testing of immune-based therapies and vaccines. Taken together, these features position organoids as a transformative tool in advancing cancer research and precision medicine.
类器官是三维干细胞衍生模型,与传统的二维细胞培养或动物模型相比,它能更真实地反映肿瘤生物学特性。类器官保留了人类癌症复杂的组织结构和细胞多样性,能够更准确地预测肿瘤生长、转移和药物反应。与微流控平台(如芯片器官系统)相结合,进一步增强了实时模拟肿瘤与环境相互作用的能力。当与多组学技术结合时,类器官有助于深入探索肿瘤异质性、分子机制以及个性化治疗策略的制定。类器官为研究肿瘤与免疫细胞的相互作用提供了一个平台,有助于免疫疗法和疫苗的设计与测试。综上所述,这些特性使类器官成为推动癌症研究和精准医学发展的变革性工具。